Other antibodies included anti-Strep (1:10,000, IBA, #2-1509-001, GmbH, Germany), Alexa Fluor 594-conjugated anti-rabbit IgG (1:200, Invitrogen, A11037), and anti-p-EPRS1 Ser990 (1:500
In rat studies, BPC-157 demonstrated healing effects in various colitis models, including cysteamine-induced colitis, improved intestinal anastomosis healing, and promoted closure of gastrointestinal fistulascomplications relevant to Crohn's disease.[4][5][3] The proposed mechanisms include interaction with the nitric oxide system, angiogenic effects, endothelium protection, and modulation of growth factor expression.[1][6] Critical limitations include the lack of published results from controlled human trials, absence of FDA approval, and concerns about products being sold online without regulatory oversight.[2] The peptide was temporarily banned by the World Anti-Doping Agency in 2022, though it is not currently listed as banned.[2] Given these limitations, BPC-157 cannot be recommended as standard therapy for ulcerative colitis or Crohn's disease based on current evidence
Rapid and reversible photoinduced switching of a rotaxane crystal
Although anammox-based nitrogen removal offers substantial reductions in energy use (up to 60%) and GHG emissions (up to 90%) by directly converting ammonium and nitrite to nitrogen gas under anoxic conditions, its application remains mostly restricted to side-stream treatment of high-strength wastewaters
